Rahul Ballal, Imara
As sickle cell patients find new options, NEA-founded Imara pitches mid-stage alternative for $86M IPO
November 2019 proved to be a fruitful month for patients with blood disorders known as hemoglobinopathies. Within days, the FDA ushered two drugs for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
